Blar i forfatter "Mølstad, Per"

Viser treff 1-3 av 3

    • Analyses of Increased Mortality in New and Known Diabetes in Patients with Coronary Disease Enrolled in the NORSTENT Randomized Study 

      Mølstad, Per; Nordrehaug, Jan Erik; Steigen, Terje; Wilsgaard, Tom; Wiseth, Rune; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05)
      Background: NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention with drug-eluting stents (DES) or bare-metal stents (BMS) with a 5-year follow-up. Among the patients, 5,512 had measured either fasting glucose level or percent glycated hemoglobin (HbA1c) at the index procedure. That cohort constitutes the present study population analyzing mortality and evaluating treatment ...

    • Drug-Eluting versus Bare-Metal Stents in Saphenous Vein Grafts Compared to Native Coronary Vessels: The Norwegian Coronary Stent Trial Study 

      Mølstad, Per; Nordrehaug, Jan Erik; Steigen, Terje; Wilsgaard, Tom; Wiseth, Rune; Rotevatn, Svein; Mannsverk, Jan Torbjørn; Larsen, Tommy; Larsby, Kristina; Skarstad, Sigrun; Fosse, Eivind Øygard; Dahl-Eriksen, Øystein; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-01)
      Background: Drug-eluting stents (DES) reduce target lesion revascularization (TLR) with no effect on mortality or myocardial infarction (MI) compared to bare-metal stents (BMS) in native vessels. Randomized stent studies in saphenous vein grafts (SVG) are few and the reported effects are ambiguous. The Norwegian Coronary Stent Trial study is the first to randomize lesions to percutaneous coronary ...

    • The effect of drug-eluting stents on target lesion revascularization in native coronary arteries: Results from the NORSTENT randomized study 

      Mølstad, Per; Nordrehaug, Jan Erik; Steigen, Terje; Melvær, Giil Lasse; Wilsgaard, Tom; Wiseth, Rune; Bønaa, Kaare Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-06)
      <i>Background</i>: The NORSTENT trial randomized 9,013 patients to percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) or bare-metal stent (BMS) with 5-year follow-up. No difference was found in the composite primary outcome of death from any cause and nonfatal spontaneous myocardial infarction after a median of 5 years of follow-up. Secondary outcomes included repeat ...